Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018;14:567–80.
2. Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, et al. REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. Sci Rep. 2022;12(1):11389.
3. Shram M, Henningfield J, Apseloff G, Gorodetzky C, De Martin S, Vocci F, et al. No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant. Presented at: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; Scottsdale (AZ); 31, 2022.
4. Bettini E, De Martin S, Mattarei A, Pappagallo M, Stahl SM, Bifari F, et al. The N-methyl-d-aspartate receptor blocker REL-1017 (esmethadone) reduces calcium influx induced by glutamate, quinolinic acid, and gentamicin. Pharmaceuticals (Basel). 2022;15(7):882.
5. Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani J, Carignani C, et al. Pharmacological comparative characterization of REL-1017 (esmethadone-HCl) and other NMDAR channel blockers in human heterodimeric N-methyl-d-aspartate receptors. Pharmaceuticals (Basel). 2022;15(8):997.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献